- Home
- CNI
as 11-15-2024 4:00pm EST
Stocks
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2023, CN generated CAD 16.8 billion in revenue by hauling intermodal containers (23% of consolidated revenue), petroleum and chemicals (19%), grain and fertilizers (19%), forest products (12%), metals and minerals (12%), automotive shipments (6%), and coal (6%). Other items constitute the remaining revenue.
| Founded: | 1919 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 68.5B | IPO Year: | N/A |
| Target Price: | $128.35 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Hold | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 6.29 | EPS Growth: | 15.13 |
| 52 Week Low/High: | $107.54 - $134.02 | Next Earning Date: | 10-22-2024 |
| Revenue: | $12,701,432,320 | Revenue Growth: | 1.54% |
| Revenue Growth (this year): | 3.53% | Revenue Growth (next year): | 5.45% |
Latest Canadian National Railway Company News
CNI Breaking Stock News: Dive into CNI Ticker-Specific Updates for Smart Investing
Motley Fool
2 days ago
Billionaire Bill Gates Has 80% of His $45 Billion Portfolio in Just 4 Stocks
Investing.com
6 days ago
Citi shuffles transportation stock ratings after post-election sector rally
Zacks
9 days ago
Top Analyst Reports for Oracle, Micron Technology & Medtronic
Simply Wall St.
10 days ago
Here's Why We Think Canadian National Railway (TSE:CNR) Is Well Worth Watching
GlobeNewswire
14 days ago
Tracy Robinson to Address the Scotiabank Transportation and Industrials Conference on November 13
Zacks
18 days ago
Delta Air Lines Capitalizes on Sustainability and Innovation
Argus Research
18 days ago
Analyst Report: Canadian National Railway Co.
Argus Research
18 days ago
Market Update: CNI, AMD, RCL, AGNC, NOW
Compare CNI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNI Canadian National Railway Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.